This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Persistent pulmonary hypertensin of the newborn (PPHN), a major clinical problem in the neonatal intensive care unit, can contribute significantly to morbidity and mortality in both term and preterm infants. Hypoxemic respiratory failure or PPHN can place newborns at risk for death, neurologic injury, and other morbidities. PPHN is categorized into parenchymal lung disease (meconium aspiration syndrome, respiratory distress syndrome, sepsis), idiopathic (or “black-lung”), and pulmonary hypoplasia (as seen in congenital diaphragmatic hernia). Treatment involves correction of factors that may promote vasoconstriction, mechanical ventilation to achieve optimal lung volume that may include high-frequency oscillatory ventilation, medical optimization of cardiac output and left ventricular function, and inhaled nitric oxide. A number of alternative and emerging pulmonary vasodilators are being investigated.
- Copyright © 2007 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.